BMS Archive

Fungi · Scientific monograph

Flammulina velutipes

Enoki / Winter Mushroom

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Immunological Research, Cellular & Immune Studies, Cardiovascular System

Research overview

Historical use

Widely consumed as food in East Asia for centuries. Known in Japan as 'Enokitake', in China as 'Jin Zhen Gu' (golden needle mushroom). Used in TCM for liver disease, gastric disorders, and as a tonic. The wild form (brown, thick-stemmed) differs significantly in bioactive content from the commercially cultivated white, slender variety.

Modern research context

Polysaccharides from F. velutipes demonstrate immunomodulatory, antioxidant, and anti-tumour activities with diverse structural and functional properties [1][5]. Renoprotective effects have been documented in chronic kidney disease models [2]. Protective activity against cisplatin-induced acute kidney injury has been observed in preclinical settings [3]. Flammutoxin, a cardiotoxic protein present in the raw mushroom, is inactivated by cooking — an important safety consideration [4]. Ergothioneine content is among the highest of edible mushrooms, contributing to its antioxidant profile [1].

Adverse effects

Raw mushroom consumption can cause GI irritation and potential cardiotoxicity (flammutoxin) — cooking is required to inactivate flammutoxin. Cooked or dried preparations are well tolerated based on long-standing culinary use; rare hypersensitivity reactions have been reported.

Contraindications

Raw consumption contraindicated. Rare mushroom allergy. No other well-established contraindications at dietary levels.

Clinical and phytochemical data

Used part

Fruiting body (cooked or extracted)

Primary active compounds

  • FVE (Flammulina velutipes immunomodulatory protein / lectin)

  • Flammulin (lectin)

  • Flammutoxin (cytotoxic protein — destroyed by heat)

  • Polysaccharides (beta-glucans)

  • L-ergothioneine

  • Profungin

Mechanism of action

FVE activates macrophages and NK cells; stimulates Th1 cytokines (IFN-γ, IL-2). Flammulin inhibits protein synthesis in cancer cells via ribosome inactivating protein (RIP)-like activity. Lectins act as TLR-4 ligands, activating innate immunity. Proflamin targets CD4+ T-cells as an immunomodulatory lectin.

Pharmacokinetics

Absorption

Absorption is compound-dependent. L-ergothioneine, which is present in Flammulina velutipes, is avidly absorbed after oral administration in healthy humans, with rapid and significant elevations in plasma and whole blood concentrations confirmed in a controlled clinical trial [1]. No human absorption data exist for FVE (immunomodulatory protein), flammulin, or the beta-glucan fractions — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ergothioneine absorbed via organic cation transporter OCTN1; accumulates selectively in tissues under oxidative stress. FVE and flammulin are proteins largely degraded during digestion; immunological activity may be mediated at mucosal level.

Distribution

L-ergothioneine distributes extensively into whole blood and erythrocytes after oral dosing in humans, accumulating via the OCTN1 transporter [1]. Distribution of FVE protein and polysaccharide fractions has not been characterised in humans — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — FVE (Flammulina velutipes lectin) and high-MW polysaccharides primarily act at mucosal surfaces and GALT. Flammulin distributes preferentially to actively dividing cells. Ergothioneine accumulates in erythrocytes via the OCTN1 transporter. No formal human PK distribution data.

Metabolism

L-ergothioneine undergoes partial in vivo biotransformation in humans; whole blood concentrations of hercynine and S-methyl-ergothioneine correlate with ergothioneine levels following oral dosing [1]. No human metabolic data exist for other Flammulina velutipes constituents — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ergothioneine: not significantly metabolised; retained in erythrocytes and mitochondria-rich tissues. Protein bioactives: digested to peptides/amino acids.

Excretion

L-ergothioneine is largely retained by the body after oral dosing in humans; urinary excretion accounts for less than 4% of the administered dose [1]. Renal and biliary excretion of other constituents has not been characterised in humans — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ergothioneine: renal excretion of intact molecule and metabolites.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

Flammutoxin is heat-labile and destroyed at cooking temperatures (>70°C); cooked preparations are non-toxic. LD50 of whole cooked extract >5 g/kg in rodents. No organ toxicity documented with cooked/extracted forms.

Special precautions

Pregnancy

Dietary consumption of cooked mushroom considered safe. Raw consumption must be avoided. Concentrated extracts — insufficient data.

Lactation

Dietary cooked consumption likely safe. No data on concentrated extract transfer to breast milk.

Hepatic impairment

No hepatotoxicity documented with cooked preparations. Standard monitoring with concentrated extracts.

Renal impairment

No specific risk identified. Ergothioneine is renally excreted; accumulation possible in severe renal failure — monitor.

Sources and references

  1. [1] - Ye S., "Research progress and future development potential of Flammulina velutipes polysaccharides.", Int J Biol Macromol, 2024, PMID: 38599436
  2. [2] - Lee MM., "Renoprotective Effects of Brown-Strain Flammulina velutipes Singer in Chronic Kidney Disease.", Int J Mol Sci, 2024, PMID: 39596166
  3. [3] - Tu Y., "Flammulina Velutipes polysaccharides ameliorate cisplatin-induced acute kidney injury in mice.", Int J Biol Macromol, 2025, PMID: 39706410
  4. [4] - Mustonen AM., "Myo- and cardiotoxic effects of the wild winter mushroom (Flammulina velutipes) on mice.", Exp Biol Med (Maywood), 2018, PMID: 29495884
  5. [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265

Additional source links

Continue browsing